Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Fibrobiologics' cell therapy CYMS101 significantly increased myelin production and promoted myelin repair in a mouse model of ...

Using approved MS drug Copaxone during pregnancy or breastfeeding does not appear to raise the risk of problems for the child ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The AI models occasionally altered decisions based on patients’ personal characteristics, affecting priority for care and ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood ...

Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...